Media Statement related to the latest public health measures
News provided by
Share this article
Share this article
TORONTO, April 1, 2021 /CNW/ - While the tightening of public health measures across Ontario must occur given the exponential growth of COVID-19 and its variants, the Ontario Nurses Association (ONA) is deeply disappointed that the Ford government has failed to implement funding for workers who are forced to self-isolate due to exposure or who are off sick.
Nurses and health-care professionals continue to be at great risk for contracting COVID-19 due to exposure to confirmed and suspected cases. When they are forced to self-isolate or are ill due to COVID-19, some are unable to access pay benefits because they work part-time or casual. No one should have to experience personal economic hardship for caring for their patients, residents and clients.
Share this article
NEW YORK, April 1, 2021 /PRNewswire/
The anti-obesity drugs market is poised to grow by $ 454.51 mn during 2021-2025, decelerating at a CAGR of 5% during the forecast period.
Technavio has announced its latest market research report titled Anti-obesity Drugs Market by Type, Mechanism Action, and Geography - Forecast and Analysis 2021-2025
View Our Exclusive report on Market scenarios, Estimates, the impact of lockdown, and Customer Behaviour.
The report on the anti-obesity drugs market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. There is an increasing need for drugs that show sustained, long-term efficacy, which, in turn, is providing immense opportunities for vendors in the market to come up with innovative products. The market is driven by a limited numb
US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002
USA - English
Share this article
Share this article
SHANGHAI, April 2, 2021 /PRNewswire/ On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States.
Preclinical data showed that JMB2002 can precisely occupy the key epitope of the receptor binding domain (RBD) on the S1 subunit of the SARS-CoV-2 with human angiotensin-converting enzyme II (hACE2) binding interface, and has strong binding and blocking activities to the spike glycoproteins of mutant viruses including the South African mutant (B.1.351), the UK mutant (B.1.1.7) and the Brazilian mutant (P.1) .
Share this article
Share this article
WASHINGTON, April 2, 2021 /PRNewswire/ The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of evidence, science and medical innovation, today announced the appointment of veteran drug pricing and health policy expert John M. O Brien, Pharm.D., MPH, as president and chief executive officer.
O Brien, who will assume the role on June 1, will be responsible for overseeing NPC s policy research and communications capacity, partnerships with other health care organizations, and strategic vision.
The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of evidence, science and medical innovation, announced the appointment of veteran drug pricing and health policy expert John M. O’Brien, Pharm.D., MPH, as president and chief executive officer.
/CNW/ - The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular.